Home › Companies › INTELLIA THERAPEUTICS INC. › 2023-2024

INTELLIA THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and INTELLIA THERAPEUTICS INC.’s Form 8-K, filed 2024-06-13 (Item 5.07 on EDGAR). Page generated 04 October 2026.

8Reported items
345Asset managers
1,877Fund votes
2024-06-12Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore INTELLIA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by INTELLIA THERAPEUTICS INC.

These tallies are INTELLIA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-13 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

INTELLIA THERAPEUTICS INC. — official shareholder meeting results, meeting held 2024-06-12
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Fred Cohen, M.D., D.Phil.	65,390,554	--	--	6,655,846	11,843,099	Majority: yes
Elect Director: Frank Verwiel, M.D.	55,820,159	--	--	16,226,241	11,843,099	Majority: yes

Source: INTELLIA THERAPEUTICS INC., Form 8-K, filed with the SEC on 2024-06-13 — read the filing on EDGAR.

How asset managers voted at the INTELLIA THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 345 asset managers that disclosed a INTELLIA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of INTELLIA THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approve, on a non-binding advisory basis, the compensation of the named executive officers.

COMPENSATION

Combines 9 wordings of this item as funds reported it.

99% fund support · no official result

FOR 99%

The 323 asset managers below cast 99% of the shares they voted on this item FOR (73,397,718 for, 1,027,306 against).

FOR: 73,397,718 (98.6%)AGAINST: 1,027,306 (1.4%)ABSTAIN: 19,095 (0.0%)NOT VOTED: 10,203 (0.0%)

Largest asset managers voting on “Approve, on a non-binding advisory basis, the compensation of the named executive officers.” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	12,389,670	0	For
ARK ETF Trust	9,826,734	0	For
State Street	6,593,527	0	For
Deep Track Capital, LP	4,236,986	0	For
Fidelity	4,096,717	9,629	For
Wellington	3,940,032	0	For
Federated Hermes	3,859,400	0	For
BlackRock	3,447,584	0	For
Nikko Asset Management Americas, Inc.	3,026,600	0	For
T. Rowe Price	2,728,933	0	For
AllianceBernstein	1,939,797	0	For
Charles Schwab	1,474,957	0	For
Contrarius Investment Management Ltd	1,450,033	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,137,075	0	For
CHEVY CHASE TRUST Co	1,033,843	0	For
Morgan Stanley	708,725	0	For
PICTET ASSET MANAGEMENT SA	693,563	0	For
Dimensional	670,772	0	For
Northern Trust	506,774	59	For
Two Sigma	501,567	0	For
MPM BioImpact LLC	433,941	0	For
Nuveen	383,847	0	For
Equitable	380,944	0	For
Goldman Sachs	376,946	0	For
TIAA	369,033	0	For

Showing the 25 largest of 323 asset managers. See all 323 in the interactive database.

2. Approval of a second amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to limit the liability of certain officers of the Company as permitted by recent amendments to the Delaware General Corporation Law.

CORPORATE GOVERNANCE

Combines 3 wordings of this item as funds reported it.

99% fund support · no official result

FOR 99%

The 85 asset managers below cast 99% of the shares they voted on this item FOR (37,098,648 for, 414,298 against).

FOR: 37,098,648 (98.8%)AGAINST: 414,298 (1.1%)ABSTAIN: 19,095 (0.1%)

Largest asset managers voting on “Approval of a second amendment to our Second Amended and Restated Certificate of Incorporation, as amended, to” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	12,223,933	0	For
ARK ETF Trust	9,826,734	0	For
Fidelity	2,579,277	0	For
State Street	2,466,056	4,173	For
Federated Hermes	1,929,700	0	For
BlackRock	1,404,146	0	For
T. Rowe Price	1,179,178	0	For
Charles Schwab	730,022	0	For
AllianceBernstein	546,754	0	For
Dimensional	510,760	0	For
Equitable	380,944	0	For
TIAA	369,033	0	For
AB DISCOVERY GROWTH FUND, INC.	304,792	0	For
Morgan Stanley	269,635	0	For
AMERICAN BEACON FUNDS	252,270	0	For
Global X	0	174,665	Against
QUANTITATIVE MASTER SERIES LLC	167,097	0	For
Direxion Shares ETF Trust	162,429	0	For
Goldman Sachs	160,000	0	For
Hartford	159,764	0	For
Aberdeen	154,269	0	For
Principal	120,199	0	For
JPMorgan	0	109,027	Against
Jackson National	94,561	0	For
Lincoln Financial	82,082	6,236	For

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

3. Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027: Frank Verwiel, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD 23%

FOR: 55,820,159WITHHELD: 16,226,241

INTELLIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Frank Verwiel, M.D.”): 55,820,159 for, 16,226,241 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,333,373 outstanding shares: 58% for, 17% withheld (75% of the company cast a for/withheld vote).

The 85 asset managers below cast 99.9% of the shares they voted on this item FOR (34,602,219 for, 70 against).

FOR 92%8%

FOR: 34,602,219 (92.2%)AGAINST: 70 (0.0%)ABSTAIN: 2,929,752 (7.8%)

Largest asset managers voting on “Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a t” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	12,223,933	0	For
ARK ETF Trust	9,826,734	0	For
Fidelity	2,559,299	19,978	For
State Street	2,434,828	35,401	For
Federated Hermes	1,929,700	0	For
BlackRock	1,404,146	0	For
T. Rowe Price	1,179,178	0	For
Charles Schwab	730,022	0	For
AllianceBernstein	0	546,754	Abstain
Dimensional	0	510,760	Abstain
Equitable	175,303	205,641	Abstain
TIAA	369,033	0	For
AB DISCOVERY GROWTH FUND, INC.	0	304,792	Abstain
Morgan Stanley	269,635	0	For
AMERICAN BEACON FUNDS	252,270	0	For
Global X	174,665	0	For
QUANTITATIVE MASTER SERIES LLC	167,097	0	For
Direxion Shares ETF Trust	0	162,429	Abstain
Goldman Sachs	0	160,000	Abstain
Hartford	159,764	0	For
Aberdeen	0	154,269	Abstain
Principal	579	119,620	Abstain
JPMorgan	109,027	0	For
Jackson National	0	94,561	Abstain
Lincoln Financial	79,536	8,782	For

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

4. Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027: Fred Cohen, M.D., D.Phil.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 65,390,554WITHHELD: 6,655,846

INTELLIA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Fred Cohen, M.D., D.Phil.”): 65,390,554 for, 6,655,846 withheld, per its Form 8-K filed 2024-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 96,333,373 outstanding shares: 68% for, 7% withheld (75% of the company cast a for/withheld vote).

The 85 asset managers below cast 100% of the shares they voted on this item FOR (33,600,653 for, 0 against).

FOR 90%10%

FOR: 33,600,653 (89.5%)ABSTAIN: 3,931,388 (10.5%)

Largest asset managers voting on “Election of Directors. Election of the following individuals nominated to serve as Class II directors, for a t” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	12,223,933	0	For
ARK ETF Trust	9,826,734	0	For
Fidelity	2,559,299	19,978	For
State Street	2,463,328	6,901	For
Federated Hermes	0	1,929,700	Abstain
BlackRock	1,404,146	0	For
T. Rowe Price	1,179,178	0	For
Charles Schwab	730,022	0	For
AllianceBernstein	0	546,754	Abstain
Dimensional	0	510,760	Abstain
Equitable	175,303	205,641	Abstain
TIAA	369,033	0	For
AB DISCOVERY GROWTH FUND, INC.	0	304,792	Abstain
Morgan Stanley	269,635	0	For
AMERICAN BEACON FUNDS	252,270	0	For
Global X	174,665	0	For
QUANTITATIVE MASTER SERIES LLC	167,097	0	For
Direxion Shares ETF Trust	162,429	0	For
Goldman Sachs	160,000	0	For
Hartford	159,764	0	For
Aberdeen	154,269	0	For
Principal	10,564	109,635	Abstain
JPMorgan	0	109,027	Abstain
Jackson National	78,755	15,806	For
Lincoln Financial	77,243	11,075	For

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

5. Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2024

AUDIT-RELATED

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 85 asset managers below cast 99.9% of the shares they voted on this item FOR (37,508,773 for, 4,173 against).

FOR: 37,508,773 (99.9%)AGAINST: 4,173 (0.0%)ABSTAIN: 19,095 (0.1%)

Largest asset managers voting on “Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accountin” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	12,223,933	0	For
ARK ETF Trust	9,826,734	0	For
Fidelity	2,579,277	0	For
State Street	2,466,056	4,173	For
Federated Hermes	1,929,700	0	For
BlackRock	1,404,146	0	For
T. Rowe Price	1,179,178	0	For
Charles Schwab	730,022	0	For
AllianceBernstein	546,754	0	For
Dimensional	510,760	0	For
Equitable	380,944	0	For
TIAA	369,033	0	For
AB DISCOVERY GROWTH FUND, INC.	304,792	0	For
Morgan Stanley	269,635	0	For
AMERICAN BEACON FUNDS	252,270	0	For
Global X	174,665	0	For
QUANTITATIVE MASTER SERIES LLC	167,097	0	For
Direxion Shares ETF Trust	162,429	0	For
Goldman Sachs	160,000	0	For
Hartford	159,764	0	For
Aberdeen	154,269	0	For
Principal	120,199	0	For
JPMorgan	109,027	0	For
Jackson National	94,561	0	For
Lincoln Financial	88,318	0	For

Showing the 25 largest of 85 asset managers. See all 85 in the interactive database.

6. 14A Executive Compensation

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

99.7% fund support · no official result

FOR 99.7%

The 7 asset managers below cast 99.7% of the shares they voted on this item FOR (172,062 for, 400 against).

FOR: 172,062 (99.7%)AGAINST: 400 (0.2%)ABSTAIN: 45 (0.0%)

Largest asset managers voting on “14A Executive Compensation” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Orchard Capital Management, LLC	160,605	0	0	For
Ultimus Managers Trust	10,915	0	0	For
NICHOLS & PRATT ADVISERS LLP /MA	0	400	0	Against
TOWNSEND ASSET MANAGEMENT CORP /NC/ /ADV	312	0	0	For
PEDDOCK CAPITAL ADVISORS, LLC	202	0	0	For
Investment Partners Asset Management, Inc.	0	0	45	Abstain
GRIMES & COMPANY, INC.	28	0	0	For

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTESSECTION 14A SAY-ON-PAY VOTESSECTION 14A SAY-ON-PAY VOTESSECTION 14A SAY-ON-PAY VOTES

99.2% fund support · no official result

FOR 99.2%

The 7 asset managers below cast 99.2% of the shares they voted on this item FOR (1,896,853 for, 14,419 against).

FOR: 1,896,853 (99.2%)AGAINST: 14,419 (0.8%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Rokos Capital Management LLP	1,463,630	0	For
JPMorgan	409,623	0	For
Advisors' Inner Circle Fund III	23,052	0	For
Desjardins Global Asset Management Inc.	0	14,419	Against
TD ASSET MANAGEMENT INC	250	0	For
SCHARF INVESTMENTS, LLC	228	0	For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	70	0	For

8. Ratify Appointment of IndependentAuditors

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (33,967 for, 0 against).

FOR: 33,967 (100.0%)

Largest asset managers voting on “Ratify Appointment of IndependentAuditors” at INTELLIA THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
Advisors' Inner Circle Fund III	23,052	0	0	0	For
Ultimus Managers Trust	10,915	0	0	0	For

Largest INTELLIA THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked by the number of INTELLIA THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 96,333,373 shares outstanding at the time of that meeting.

Top INTELLIA THERAPEUTICS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	12.86%
2	ARK ETF Trust	10.20%
3	State Street	6.84%
4	Deep Track Capital, LP	4.40%
5	Fidelity	4.26%
6	Wellington	4.09%
7	Federated Hermes	4.01%
8	BlackRock	3.58%
9	Nikko Asset Management Americas, Inc.	3.14%
10	T. Rowe Price	2.83%

Reported INTELLIA THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

INTELLIA THERAPEUTICS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	11.47%	13F
BlackRock	9.63%	13F
Morgan Stanley	6.25%	13F
State Street	4.77%	13F
Goldman Sachs	4.44%	13F
Wellington Management	4.32%	13F
Geode Capital	2.12%	13F
FMR (Fidelity)	1.92%	13F
T. Rowe Price	1.69%	13F
Dimensional Fund Advisors	1.27%	13F

Percentages above are of 96,333,373 shares outstanding, as reported by INTELLIA THERAPEUTICS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from INTELLIA THERAPEUTICS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At INTELLIA THERAPEUTICS INC.'s shareholder meeting held 2024-06-12, in the 2023-2024 proxy season, 345 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,877 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. INTELLIA THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Approve, on a non-binding advisory basis, the compensation of the named executive officers. — the reporting funds cast 99% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

INTELLIA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.